MEDIF
Price
$0.05
Change
-$0.00 (-0.00%)
Updated
Sep 5 closing price
Capitalization
22.84M
MEDXF
Price
$2.20
Change
-$0.00 (-0.00%)
Updated
Sep 5 closing price
Capitalization
71.91M
60 days until earnings call
Interact to see
Advertisement

MEDIF vs MEDXF

Header iconMEDIF vs MEDXF Comparison
Open Charts MEDIF vs MEDXFBanner chart's image
Medipharm Labs
Price$0.05
Change-$0.00 (-0.00%)
Volume$48.26K
Capitalization22.84M
Medexus Pharmaceuticals
Price$2.20
Change-$0.00 (-0.00%)
Volume$1K
Capitalization71.91M
MEDIF vs MEDXF Comparison Chart in %
Loading...
MEDIF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MEDXF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MEDIF vs. MEDXF commentary
Sep 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MEDIF is a Hold and MEDXF is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 07, 2025
Stock price -- (MEDIF: $0.05 vs. MEDXF: $2.20)
Brand notoriety: MEDIF and MEDXF are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: MEDIF: 40% vs. MEDXF: 8%
Market capitalization -- MEDIF: $22.84M vs. MEDXF: $71.91M
MEDIF [@Pharmaceuticals: Generic] is valued at $22.84M. MEDXF’s [@Pharmaceuticals: Generic] market capitalization is $71.91M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.95B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.93B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MEDIF’s FA Score shows that 0 FA rating(s) are green whileMEDXF’s FA Score has 1 green FA rating(s).

  • MEDIF’s FA Score: 0 green, 5 red.
  • MEDXF’s FA Score: 1 green, 4 red.
According to our system of comparison, MEDXF is a better buy in the long-term than MEDIF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MEDIF’s TA Score shows that 3 TA indicator(s) are bullish while MEDXF’s TA Score has 5 bullish TA indicator(s).

  • MEDIF’s TA Score: 3 bullish, 7 bearish.
  • MEDXF’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, MEDXF is a better buy in the short-term than MEDIF.

Price Growth

MEDIF (@Pharmaceuticals: Generic) experienced а -9.19% price change this week, while MEDXF (@Pharmaceuticals: Generic) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.10%. For the same industry, the average monthly price growth was +12.13%, and the average quarterly price growth was +87.01%.

Reported Earning Dates

MEDXF is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.10% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MEDXF($71.9M) has a higher market cap than MEDIF($22.8M). MEDIF YTD gains are higher at: 25.327 vs. MEDXF (-8.903). MEDXF has higher annual earnings (EBITDA): 17.8M vs. MEDIF (-4.75M). MEDIF (8.44M) and MEDXF (8.44M) have equal amount of cash in the bank . MEDIF has less debt than MEDXF: MEDIF (125K) vs MEDXF (39.9M). MEDXF has higher revenues than MEDIF: MEDXF (110M) vs MEDIF (43M).
MEDIFMEDXFMEDIF / MEDXF
Capitalization22.8M71.9M32%
EBITDA-4.75M17.8M-27%
Gain YTD25.327-8.903-284%
P/E RatioN/A110.00-
Revenue43M110M39%
Total Cash8.44M8.44M100%
Total Debt125K39.9M0%
FUNDAMENTALS RATINGS
MEDIF vs MEDXF: Fundamental Ratings
MEDIF
MEDXF
OUTLOOK RATING
1..100
5024
VALUATION
overvalued / fair valued / undervalued
1..100
91
Overvalued
82
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9566
PRICE GROWTH RATING
1..100
5949
P/E GROWTH RATING
1..100
1008
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MEDXF's Valuation (82) in the null industry is in the same range as MEDIF (91). This means that MEDXF’s stock grew similarly to MEDIF’s over the last 12 months.

MEDXF's Profit vs Risk Rating (100) in the null industry is in the same range as MEDIF (100). This means that MEDXF’s stock grew similarly to MEDIF’s over the last 12 months.

MEDXF's SMR Rating (66) in the null industry is in the same range as MEDIF (95). This means that MEDXF’s stock grew similarly to MEDIF’s over the last 12 months.

MEDXF's Price Growth Rating (49) in the null industry is in the same range as MEDIF (59). This means that MEDXF’s stock grew similarly to MEDIF’s over the last 12 months.

MEDXF's P/E Growth Rating (8) in the null industry is significantly better than the same rating for MEDIF (100). This means that MEDXF’s stock grew significantly faster than MEDIF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MEDIFMEDXF
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
83%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
N/A
Bullish Trend 4 days ago
83%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 9 days ago
83%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
89%
Bearish Trend 2 days ago
83%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
69%
View a ticker or compare two or three
Interact to see
Advertisement
MEDIF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MEDXF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ELEZY15.230.38
+2.53%
Endesa S.A.
AAGRY1.66N/A
N/A
Astra Agro Lestari TBK
HEWA0.10N/A
N/A
HealthWarehouse.com, Inc.
HKMPY46.95N/A
N/A
Hikma Pharmaceuticals plc.
ESTTF5682155.00N/A
N/A
Estore Corp.

MEDXF and

Correlation & Price change

A.I.dvisor tells us that MEDXF and LBTSF have been poorly correlated (+10% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MEDXF and LBTSF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MEDXF
1D Price
Change %
MEDXF100%
N/A
LBTSF - MEDXF
10%
Poorly correlated
N/A
MRMD - MEDXF
9%
Poorly correlated
-8.53%
MKGAF - MEDXF
7%
Poorly correlated
+1.49%
MCUJF - MEDXF
4%
Poorly correlated
N/A
MEDIF - MEDXF
2%
Poorly correlated
-1.26%
More